Innovation Saving Lives

We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch™, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification.

EpiSwitch™ biomarkers based on chromosomal conformation signatures are a critical cog in personalised medicine.

Technology to select the right drug at the right dose at the right time for the right patient.

EpiSwitch™ captures the heterogeneity of the environment on the genome.

Our Publications on Episwitch™


A Prospective Study of Two Distinct Epigenetic Signatures for ALS Diagnosis and Prognosis.

Westra, W, et. al.,
16th Annual Northeast Amyotrophic Lateral Sclerosis Meeting
http://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/NEALS_2017_ALS_Biomarker.pdf

Epigenetic signatures and early detection of neurodegenerative diseases: Development of stratifying biomarker for ALS in Asian cohorts.

Lim, CR, et. al.,
World Congress of Neurology
https://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/ALSposter_WCN2017Kyoto_Final.pdf

PerkinElmer releases application note outlining the importance of EpiSwitch™ technology in determining epigenetic biomarkers using the LabChip GX Touch Platform.

OBD and PerkinElmer
Application Note; 25 August 2017
https://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/013589_01EpiGenetics-Biomarkers-APP.pdf

Super-Enhancers and Broad H3K4me3 Domains Form Complex Gene Regulatory Circuits Involving Chromatin Interactions.

Cao, F, et. al.,
Scientific Reports
https://www.nature.com/articles/s41598-017-02257-3

Chromatin Conformation Signatures Associated with Epigenetic Deregulation of the FIP1L1 and PDGFRA Genes.

Grand, FH, et. al.,
American Society of Haematology
https://ash.confex.com/ash/2016/webprogram/Paper90884.html

Epigenetic footprints for neurodegenerative and autoimmune conditions: a comparative analysis.

Hunter, E, et. al.,
The Lancet Neurology Conference
http://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/2016-LNC-Epigenetic-footprints-for-neurodegenerative-and-autoimmune-conditions.pdf

Epigenetic signatures and early detection of neurodegenerative diseases.

Salter, M., et. al.,
The Lancet Neurology Conference
http://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/2016-LNC-Epigenetic-signatures-and-early-detection-of-neurodegenerative-diseases.pdf

Chromosome conformation capture to discover candidate epigenetic markers of Multiple Sclerosis disease severity.

Sangurdekar, D., et. al.,
32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
http://onlinelibrary.ectrims-congress.eu/ectrims/2016/32nd/146797/tatiana.plavina.chromosome.conformation.capture.to.discover.candidate.html?f=m3

Epigenetic profile of chromosome conformation signatures underlying multiple sclerosis and its severity.

Joesph, JP., et. al.,
32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
http://onlinelibrary.ectrims-congress.eu/ectrims/2016/32nd/146441/joyce.joseph.epigenetic.profile.of.chromosome.conformation.signatures.html?f=m3

Systemic Epigenetic Biomarkers for ALS Improve Early Diagnosis, Treatment and Trials.

Jeznach, M.
International Pharmaceutical Industry
https://issuu.com/mark123/docs/ipi_march2016_web/45